11/5/2026

speaker
Operator
Conference Call Operator

Good day and welcome to the Vera Therapeutics Business Update and Financial Results webcast for the quarter ended September 30th, 2026. At this time, all participants are in listen-only mode. A question and answer session will follow the prepared remarks. As a reminder, this webcast is being recorded. If you have any objections, please disconnect at this time. I would now like to turn the call over to Josh Chin, Vice President of Corporate Finance and Investor Relations at Vera.

speaker
Josh Chin
Vice President of Corporate Finance and Investor Relations

Please go ahead. Thank you, Operator, and thank you, everyone, for joining us. Earlier today, we issued a press release announcing our business highlights and financial results for the quarter ended September 30, 2026. A copy of the press release is available in the Investors and Media section of our website at ir.veratx.com. Before we begin, I would like to remind everyone that we will be making various remarks about future expectations, plans, and prospects, which constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The company cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated. Thank you for watching. In addition, today's discussion includes results from ongoing clinical trials of Atacicept in investigational uses that have not been approved by the FDA or any other regulatory authority. The full prescribing information for Trutacna, including important safety information, is available on our website. Furthermore, the content of this webcast contains time-sensitive information that is accurate only as of the date of the live broadcast, November 5, 2026. VERA undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this broadcast. This webcast is being recorded and an archive will be available on our website for 30 days. With that, I will turn the call over to Dr. Marshall Fordyce, Founder and Chief Executive Officer. Marshall?

speaker
Dr. Marshall Fordyce
Founder and Chief Executive Officer

Thank you, Josh, and welcome, everyone. Joining me today are Dr. Robert Brenner, our Chief Medical Officer, Matt Skelton, our Chief Commercial Officer, and Sean Grant, our Chief Financial Officer. The third quarter marked a major turning point for Vera. Following accelerated approval from the FDA in July, we launched Trutacna, the first therapy approved in the U.S. that targets both Bath and April to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. Since the accelerated approval of Trutacna on July 7th, We have received approximately 700 patient start forms to date. This early momentum exemplifies our long-standing confidence in Trutacna's potential to become a foundational therapy for IgA nephropathy, and it represents an important first step in delivering on our commitment to people living with this disease. Thank you for watching. The Origin 3 Final Efficacy Results, presented at ASN Kidney Week in October, strengthens the clinical foundation for this next phase of growth. As Rob will discuss, in the Origin 3 final efficacy analysis, Trutacna held the rate of kidney function decline to a physiologic level and reduced the risk of kidney disease progression by 76% compared with placebo through 104 weeks. We are pleased with the overall product profile and believe that we have one of the most robust data packages in the B-cell modulator class. These findings build on the proteinuria reduction at 36 weeks that supported accelerated approval. This week, we submitted a supplemental biologics licensing application to the FDA seeking full approval of Trutacna in adults with primary IgA nephropathy based on the Origin 3 final efficacy analysis. In addition, following a meeting with the Committee for Medicinal Products for Human Use at the European Medicines Agency, we plan to submit a marketing authorization application in the first quarter of 2027 for standard marketing authorization. Importantly, this application will leverage the same results presented at Kidney Week. These are important regulatory milestones as we advance toward potential full FDA approval in mid-2027, with potential approvals in other regions to follow. Alongside the U.S. launch and our pursuit of full approval in the U.S. and other regions, we are advancing the ongoing development program to expand the opportunity for ATACiCEPT, This includes the Phase II Pioneer Basket Trial in broader IgA nephropathy populations and other antibody-mediated kidney diseases, including encouraging interim results presented at ASN, as well as the once-monthly dose range finding study. This integrated program reflects our ambition to build on our progress in adult IgA nephropathy and bring new treatment options to more patients over time. With the early launch progress and expanding clinical evidence, Vera is now viewed as a leading kidney disease company. We are entering this next phase with enthusiasm and a clear focus on execution, bringing Trutacna to more eligible patients today while developing opportunities to improve care for more patients in the future. With that, I'll turn the call over to Dr. Robert Brenner for a recap of ASN and an update on our development activities.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API